Search Results
Your search for ,NOt matches 22378 pages
Showing 251 - 300Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS
Patients with previously untreated higher-risk myelodysplastic syndromes (MDS) did not experience improved outcomes with the addition of the anti-CD47 antibody magrolimab to azacitidine compared with azacitidine alone, according to the results of the phase III ENHANCE trial reported by Sallman et...
FDA Releases Final Guidances to Expand Participation in Cancer Clinical Trials
The FDA’s Oncology Center of Excellence announced three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs. Fewer than 5% of patients with cancer currently receiving treatment are enrolled in clinical trials—even though more...
Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC
As reported in The Lancet Oncology by Brunetti et al, a post hoc analysis of the phase III PACIFIC trial showed that baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes among patients with unresectable stage III non–small cell lung cancer (NSCLC)...
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E–Positive Differentiated Thyroid Cancer
In a global phase III trial reported in The Lancet Oncology by Gao et al, dabrafenib plus trametinib significantly improved progression-free survival and overall response rate compared with placebo in previously treated patients with locally advanced or metastatic, radioactive iodine–refractory,...
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
In a phase I clinical trial, treatment with the investigational FcRH5×CD3 bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma—many of whom had already been through multiple other cancer treatments—and produced a median duration of response of 11.2 months ...
Proposed Rule Changing Federal Grantmaking Will Have Devastating Impact on Cancer Research, Patients
The Association for Clinical Oncology (ASCO) is urging the Office of Management and Budget (OMB) to significantly revise a proposed rule that would allow federal agencies to terminate grants at any time based on shifting agency priorities, and subject grant approvals to a pre-issuance review by...
Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth
Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything about her as a scientist, a clinician, and a person. She was direct with compassion, generous to the ...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
Electronic Prior Authorization Requirements for Drugs
The Association for Clinical Oncology (ASCO) submitted formal comments (see https://bit.ly/4xYRg1j) to the Centers for Medicare & Medicaid Services (CMS) in response to the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule. If finalized, this rule will require...
ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical questions: when ctDNA testing should (or should not) be used to (1) support cancer diagnosis; (2)...
Access Denied: Insurance Barriers to Biomarker Testing in Lung Cancer
In the past few decades, the rapidly growing field of precision medicine has improved the survival of patients with lung cancer. Yet the benefits of these therapies do not reach all patients. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, yet most patients are diagnosed ...
Cancer Survivors and Providers Differ on Cannabis Risk Awareness and Communication
As reported in the Journal of Cancer Education by Kim et al, parallel surveys of cancer survivors and cancer care providers showed gaps in risk awareness and communication about cannabis use. underscoring the need for open, nonjudgmental dialogue and clinical guidance. Although attitudes toward...
Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China
Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherapy produced high pathologic response rates in patients in China with HER2-positive locally advanced...
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
On July 22, the U.S. Food and Drug Administration (FDA) approved zidesamtinib (Jideytro), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The approval...
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
According to the results of the phase III POLARGO trial reported by Matasar et al in the Journal of Clinical Oncology, adding polatuzumab vedotin-piiq to rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) significantly improved overall survival compared with standard rituximab, gemcitabine, and ...
ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field
The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments for amyloidosis will appear in a separate article. Mezigdomide-Based Regimen Improves...
Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?
Consolidative thoracic radiotherapy added to standard maintenance immunotherapy increased toxicity without improving survival in first-line extensive-stage small cell lung cancer (SCLC), according to findings from the multicenter phase II TREASURE (AIO-TRK-0320) trial published in JAMA Oncology....
Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer
In a cohort study of patients with nonmetastatic colorectal cancer, treatment delays were associated with a higher risk of metastasis, with the magnitude differing by treatment pathway. Nguyen et al published the findings in JAMA Network Open. “These results suggest that pathway-specific thresholds ...
Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma
A research team has reported that a groundbreaking pathway-targeted therapy may be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease. Martin McMahon, PhD, Senior Director of Preclinical Translation at Huntsman Cancer Institute...
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
Diagnosis of a cancer upon emergency department presentation was associated with an elevated mortality rate, which was consistent across 16 analyzed cancer types, according to new research findings published in the Journal of the National Cancer Institute. “These gaps held up even after we...
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
A review of the scientific literature on the impact of environmental factors on the health of pediatric cancer survivors by Omar Shakeel, MD, Assistant Professor in the Department of Pediatrics, Division of Hematology-Oncology at Baylor College of Medicine and Head of the Long-Term Survivor Clinic ...
Early Trial Supports KRAS Vaccine Strategy for Pancreatic Cancer Interception
A vaccine targeting common KRAS mutations was safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma (PDAC), according to phase I clinical trial results published by Haidar et al in Cancer Discovery....
National Survey Links Civic Engagement to Higher Breast Cancer Screening Rates
Findings from a National Health Interview Survey revealed that civically engaged adults were more likely to stay up to date with their breast cancer screenings. The research findings were published in the American Cancer Society's Cancer journal. “The connection isn’t surprising, as being...
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
Oral nicotinamide (vitamin B3) may provide a cost-effective strategy for preventing keratinocyte carcinoma (KC) in persons at high risk, according to a study published in JAMA Dermatology. Led by David Perez, BA, the study was designed to determine whether the clinical benefits previously observed...
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–associated antigen 4] plus regular interval durvalumab [anti–PD-L1]) with or without lenvatinib...
Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors
In a meta-analysis published in The Oncologist, researchers found that second-generation Bruton's tyrosine kinase (BTK) inhibitors had a better cardiovascular safety profile than the first-generation BTK inhibitor ibrutinib for patients with B-cell malignancies. This led to fewer reported key...
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
Circulating tumor DNA (ctDNA) for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to findings from an overall survival analysis of the phase II GALAXY...
Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes
Researchers have created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The newly published findings provide insights that may explain why patients with similar diagnoses often have differences in disease progression, treatment ...
Expert Dermatologists Outperform AI Foundation Models in Real-World Skin Cancer Diagnosis
According to a diagnostic study reported in JAMA Dermatology by Anriot et al, a modern artificial intelligence (AI) foundation model outperformed less experienced clinicians but did not match the diagnostic performance of expert dermatologists when tested under realistic clinical conditions. The...
How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?
In a prospective, multicenter, nonrandomized patient-preference trial published in JAMA Network Open, interval salpingectomy with delayed oophorectomy (ISDO) was associated with less impairment in sexual function than risk-reducing salpingo-oophorectomy (RRSO) among premenopausal women at high risk ...
Virtual Sustained Counseling and Tobacco Treatment Improve Quit Rates for Patients With Cancer in Community Settings
Virtual sustained counseling and nicotine replacement therapy led to an almost doubling of 6-month smoking quit rates compared with standard care for patients facing a recent cancer diagnosis, according to findings from the randomized controlled ECOG-ACRIN EAQ171CD trial from the National Cancer...
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
As reported in The Lancet by Lu et al, an interim analysis of the Chinese phase III HARMONi-6 trial showed that ivonescimab plus chemotherapy was associated with significantly improved overall survival vs tislelizumab plus chemotherapy in patients with previously untreated advanced squamous...
ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment
For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance resulted in more toxicity with no survival benefit from continuing treatment until disease progression compared with stopping after 2 years. Results from the...
Addition of Sacituzumab Tirumotecan to Pembrolizumab in PD-L1–Positive Advanced NSCLC
As reported in The Lancet by Xiong et al, an interim analysis of a Chinese phase III trial (OptiTROP-Lung05) has shown that the addition of sacituzumab tirumotecan (a trophoblast cell–surface antigen 2–targeting antibody-drug conjugate) to pembrolizumab significantly prolonged progression-free...
KRAS G12D–Mutated Metastatic Pancreatic Cancer: Zoldonrasib Plus Chemotherapy
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented at the ESMO Gastrointestinal Cancers Congress 2026 (Abstract...
Over 50 Million Americans Live in Counties Without a Radiation Oncology Clinic
More than 50 million Americans live in counties without a radiation oncology practice site and millions more are at risk, according to a new study published by Yu et al in the International Journal of Radiation Oncology • Biology • Physics (Red Journal). The national analysis found that from 2018...
Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer
On July 14, the U.S. Food and Drug Administration (FDA) approved gedatolisib (Revtorpyk) in combination with fulvestrant, with or without palbociclib, for the treatment of adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA...
Setmelanotide in Patients With Acquired Hypothalamic Obesity
Setmelanotide, a melanocortin-4 receptor agonist, significantly reduced body mass index (BMI) and signs of hunger in patients with acquired hypothalamic obesity, according to findings from the phase III TRANSCEND trial published in The New England Journal of Medicine. Although focused primarily on...
Radiotherapy Dose Escalation With Intraoperative Radiotherapy vs Surgery Alone in Glioblastoma
In a phase III trial (INTRAGO-II) reported in The Lancet Oncology, Giordano et al found that the addition of intraoperative radiotherapy to surgery did not improve outcomes in patients with newly diagnosed glioblastoma. Study Details The open-label trial enrolled 298 patients (full-analysis set)...
Stage III HER2-Negative Breast Cancer With HRD: Standard Chemotherapy Plus Olaparib
In a European phase III trial (SUBITO) reported in The Lancet Oncology, Seefat et al found that intensified alkylating chemotherapy with autologous stem cell rescue (IACT) provided no overall survival advantage vs standard chemotherapy followed by olaparib in patients with stage IIIA-C...
Emergency Hospital Admission Accounts for 40% of Ovarian Cancer Diagnoses in England
About two in five women diagnosed with ovarian cancer were only diagnosed after an emergency admission to the hospital, according to the results of a national population-based study from England that was published in BMJ Oncology. “The risk of being diagnosed with ovarian cancer after an emergency ...
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases
In a phase III trial (CAIRO6) reported in The Lancet Oncology, Rovers et al found that perioperative systemic therapy was not associated with significant improvement in overall survival vs surgery alone in patients with resectable peritoneal-only metastases of colorectal adenocarcinoma. Study...
Shared Risk Factors Between Breast Cancer and Atrial Fibrillation/Flutter
Alcohol use and smoking were linked to breast cancer and atrial fibrillation/flutter in women aged 55 years and older in multiple regions of the world, according to new research published by Zhang et al in the Journal of the American Heart Association. Breast cancer and atrial fibrillation—also...
FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer
On July 10, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), each in combination with the NECTIN4-directed antibody-drug conjugate enfortumab vedotin-ejfv (Padcev), as neoadjuvant...
FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
On July 9, the U.S. Food and Drug Administration (FDA) approved the anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications. The specific indications approved for isatuximab are: In combination with pomalidomide and dexamethasone...
Long-Term Overall Survival With Addition of SBRT to Abiraterone Acetate and ADT in Oligometastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Francolini et al, an unplanned long-term analysis of overall survival in the Italian phase II ARTO trial showed a survival benefit with the addition of metastasis-directed therapy with stereotactic body radiotherapy (SBRT) to abiraterone acetate and...
Advanced Gastric or GEJ Cancer: First-Line Disitamab Vedotin, Tislelizumab, and S-1
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Li et al found that the first-line combination of disitamab vedotin, tislelizumab, and S-1 was associated with high activity in patients with HER2-overexpressing advanced gastric/gastroesophageal junction (GEJ)...
In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types
Between 2015 and 2022, men were more likely than women to be diagnosed with regional and/or distant stages of 20 nonreproductive solid cancer types in the United States, according to a study published by Maclin et al in Cancer Epidemiology, Biomarkers & Prevention. The study’s findings may...
Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma
Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published in Nature Communications. “Targeted therapy works by shutting down the main signal driving...
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
The addition of radiotherapy to the S-1 plus oxaliplatin (SOX) chemotherapy regimen did not improve disease-free or overall survival in patients with pathologic T4 and/or node-positive gastric adenocarcinoma who underwent D2 gastrectomy (ie, R0 resection with D2 lymphadenectomy), based on a phase...
